Jardiance (Empagliflozin) Cost in Canada for Diabetes Patients

Jardiance (empagliflozin) is an SGLT2 inhibitor approved in Canada for the treatment of type 2 diabetes. It works by helping the kidneys remove excess glucose through urine. Jardiance has also shown cardiovascular benefits in clinical trials, which has contributed to its growing use. Jardiance is a brand-name medication without a widely available generic alternative in Canada, which means costs tend to be higher. A 30-day supply typically costs between $90 and $130 without insurance. Provincial drug plan coverage for Jardiance varies. Ontario\'s ODB lists it through the Exceptional Access Program (EAP), meaning your physician must apply on your behalf. Other provinces may have similar restricted-access designations. Private insurance plans increasingly cover SGLT2 inhibitors, but coverage may require prior authorization or documentation of previous treatment attempts. The manufacturer, Boehringer Ingelheim, offers a patient assistance program that may help reduce out-of-pocket costs. Ask your pharmacist or physician about eligibility. Jardiance requires a prescription from a physician who manages your diabetes care. Your doctor will consider your blood sugar levels, kidney function, and other medications before prescribing. This can be discussed during an in-person or telehealth appointment. *This article is for informational purposes only.*

This article is for informational purposes only and does not constitute medical advice. Content reviewed by licensed Canadian physicians. Last updated February 2026.